Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-01
2006-08-01
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S475000, C514S478000, C514S588000, C530S300000, C530S329000, C549S332000, C560S157000, C564S032000
Reexamination Certificate
active
07084108
ABSTRACT:
The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5180735 (1993-01-01), Kishimoto et al.
patent: 5180738 (1993-01-01), Kishimoto et al.
patent: 5290807 (1994-03-01), Folkman et al.
patent: 5422363 (1995-06-01), Yanai et al.
patent: 5648382 (1997-07-01), Billington et al.
patent: 5698586 (1997-12-01), Kishimoto et al.
patent: 5767293 (1998-06-01), Oku et al.
patent: 5789405 (1998-08-01), Oku et al.
patent: 6017954 (2000-01-01), Folkman et al.
patent: 6086865 (2000-07-01), Folkman et al.
patent: 6548477 (2003-04-01), Olson et al.
patent: 2002/0193298 (2002-12-01), Olson et al.
patent: 0 354 787 (1990-02-01), None
patent: 0 357 061 (1990-03-01), None
patent: 0 359 036 (1990-03-01), None
patent: 0 387 650 (1990-09-01), None
patent: 0 415 294 A2 (1991-03-01), None
patent: WO 99/13059 (1998-04-01), None
patent: WO 98/56372 (1998-12-01), None
patent: WO 9959986 (1999-11-01), None
patent: WO 9961432 (1999-12-01), None
patent: WO 00/64486 A2 (2000-11-01), None
patent: WO 0089472 (2000-11-01), None
Griffith et al. Molecular recognition of angiogenesis inhibitors fumagillin . . . Proceedings of the National Academy of Science USA. Dec. 1998, vol. 95, pp. 15183-15188.
Denmeade Sr, et al. “Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.”Cancer Res. Jun. 15, 1998;58(12):2537-40.
Griffith EC, et al. “Molecular recognition of angiogenesis inhibitors fumagillin and ovalioin by methionine aminopeptidase 2.”Proc Natl Acad Sci U S A. Dec. 22, 1998;95(26): 15183-8.
Griffith EC, et al. “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin”,Chem Biol. 1997 Jun.;4(6):461-71.
Han CK, et al. “Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.”Bioorg Med Chem Lett. Jan. 3, 2000;10(1):39-43.
Landquist, JK “Some Degradation Products of Furnagillin”J. Chem. Soc.1956: 4237-4245.
Tarbell et al. “Chemical Evidence For At Least Two Different Precursors To Cyclohexene Formed By Electron Irradiation Of Cyclohexane” Feb. 20, 1960;1005-1007.
Liu S, et al. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. Nov. 13, 1998; 282(5392):1324-7.
Sin N, et al. “The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.”Proc Natl Acad Sci U S A. Jun. 10, 1997;94(12):6099-103.
Timar F, et al. “The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site.”Cancer Chemother Pharmacol. 1998;41(4):292-8.
Turk BE, et al. “Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells.”Chem Biol. 1999 Nov;6(11):823-33.
De Marre, A. et al. “Synthesis and evaluation of macromolecular prodrugs of mitomycin C.”Journal of Controlled Release36(1/2):87-97 (Sep. 1995).
Nichifor, M. et al. “Chemical and enzymatic hyrdolysis of dipeptide derivatives of 5-fluorouracli,”Journal of Controlled Release47:271-281 (1997).
Arico-Muendel Christopher C.
Birktoft Jens
Cook Charles Michael
Lee Lily
Morgan Barry
DeConti, Jr. Giulio A.
Laccotripe Zacharakis Maria
Lahive & Cockfield LLP
Praecis Pharmaceuticals Inc.
Russel Jeffrey Edwin
LandOfFree
Therapeutic agents and methods of use thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents and methods of use thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents and methods of use thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3627457